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SMOOTH MUSCLE CELLS FOR SYSTEMIC AND 
LOCAL THERAPY 
Smooth muscle cells are an excellent target for vascular gene 
transfer because they have many properties that make them a 
reliable and durable vector. They are the principle cellular compo- 
nent of large arteries and veins and participate invarious important 
vascular disease states, including atherosclerosis and intimal hyper- 
plasia, after vascular econstruction. The cells are readily cultured 
and, as we have shown, can be seeded back in vivo. These seeded 
cells, like their endogenous relatives, are long-lived. We have used 
vascular smooth muscle cells transduced with replication-defective 
rettovirus as a means for transferring genes into blood vessels for 
three purposes: (1) systemic gene therapy; (2) local pharmacology 
to control vascular function; and (3) the development of models of 
vascular disease. This method of transferring genes leads to stable, 
long-term expression of the vitally encoded protein because the 
transferred gene is incorporated into the host genome. A significant 
weakness in this approach is that cell culture and subsequent 
seeding back into the artery are required for efficient gene transfer. 
Because transduction with these vectors i  so poor in vivo (approxi- 
mately 1in 10,000 cells), the only efficient way to transfer the gene 
of interest isto transduce the cells in vitro and then to transfer the 
cells to the vascular site. The cells are placed into a discrete portion 
of the vasculature (e.g., an injured artery or a graft) and can be 
removed later by surgical excision, la Although there has been 
neither detectable helper virus activity nor evidence of neoplastic 
transformation in the smooth muscle cells we have studied in vivo, 
it is reassuring to have a practical means to deal with the problem 
should the need arise. 
The expression ofthe transferred gene is controlled at the level 
of transcription by the retroviral LTRs and is continuous and not 
regulatable. This limitation of the system isnot of great significance 
because the clinical problem isto obtain adequate expression ofthe 
transferred gene and not to suppress overexpression. Nevertheless, 
in the future we hope to have mechanisms for the control of the 
expression of the transferred gene. 
Systemic gene therapy 
Most of our studies have been performed insyngeneic Fischer 
344 rats using retroviral vectors developed by Miller and col- 
leagues. 1'4 These retroviral vectors do not contain the necessary 
components o encode for the coat proteins and therefore are 
replication-defective. The regulatory elements (LTRs) remain, and 
the gene of interest ogether with a selectable marker such as 
neomycin phosphotransferase (NEO) are inserted. The complete 
vector is generated bytransfecting the retroviral plasmid containing 
the gene of interest into a "packaging line" that provides the 
necessary proteins for encapsulating the genetic material. The viral 
particles generated in this manner act as one-way shuttles to infect 
vascular smooth muscle cells. As noted above, they are not capable 
of replication. In the initial experiments, he Fischer 344 rat smooth 
muscle cells were infected with retrovirus encoding either E. coli 
beta galactosidase (13 gal) or human placental alkaline phos- 
phatase. 1'~ The transduced cells are selected inthe neomycin analog 
G418. The cells stably expressing either [3 gal or alkaline phos- 
phatase are then seeded into rat carotid arteries denuded of 
endothelinm by the passage of a balloon catheter. The smooth 
muscle cells stick in regions lacking endothelinm within 15 minutes 
and remain after the circulation isrestored. Three major issues have 
been addressed. First, it appears that the cultured smooth muscle 
ceils are robust and can survive culture, retroviral infection, and 
harsh selection in vitro and still survive long term in the in vivo 
environment. Second, these cells infected with retrovirus do not 
appear to be transformed. They replicated for one or two rounds in 
the neointima nd then resume quiescence in a manner similar to 
the endogenous cells. An intima formed by seeded ceils reaches 
maximal thickness between 2 and 4 weeks after surgery and does 
not change thereafter up to 1 year. Third, the expression of the 
transferred genes appears to be durable. We have evaluated the 
expression ofa number of human and animal genes ([3 gal, human 
alkaline phosphatase, human adenosine deaminase, baboon tissue 
inhibitor of metalloproteinases-1 [TIMP-1], rat erythropoietin), 
and have found that he encoded proteins are expressed and active, 
although in some circumstances animmunologic response to the 
expressed protein has been observed (for example, to baboon 
TIMP-1). 
We have been able to demonstrate recently that the encoded 
protein can have a systemic impact. In rats seeded with smooth 
muscle cells encoding rat erythropoietin, the hematocrit levels rise 
from 45% to 60% over a period of several weeks even though 
endogenous erythropoietin expression is suppressed in these ani- 
mals. Although this systemic effect can be obtained with relatively 
few cells (approximately 10,000 to 50,000 ceils per carotid artery), 
a note ofcantion isin order. Erythropoietin is an extremely potent 
hormone, and a very small amount produces a dramatic response. 
Either more effective vectors or larger numbers of smooth muscle 
cells would be required to achieve xpression of a protein in the 
microgram-per-milliliter range. 
Models of vascular disease 
We are currently using the smooth muscle ceil-based transfer 
approach to model certain aspects of atherosclerosis. One of the 
interesting properties of atherosclerotic plaques, but not of rat 
intimal thickening, is the pronounced thrombotic activity that can 
be observed when the luminal surface is disrupted. The reason for 
this response in far-advanced atherosderotic plaques is not yet 
evident. Some investigators have proposed that the thrombotic 
activity is attributable toabnormal location and expression of two 
genes, tissue factor and plasminogen activator-1 (PAL1), in the 
plaque. Because thrombosis i  not a property of rat neointima, we 
are currently attempting tomodel human thrombosis by introduc- 
ing smooth muscle cells that overexpress either tissue factor or 
PAL1. The preliminary data support he conclusion that these 
genes may have a dramatic effect on local vascular thrombosis. 
Local pharmacology 
It would be highly dcsirable to control stenosis locally and 
avoid the systemic cffccts of the administered drug. We are 
currently using the smooth muscle cell-based gene transfer ap- 
proach to develop harmacologic strategies for controlling intimal 
hyperplasia and stenosis or restenosis after vascular surgery. In our 
initial experiments, wehave focused on the role of matrix metallo- 
proteinases in smooth muscle cell proliferation and migration and 
the development of the neointima. We have observed that two 
matrix metalloproteinases (72kD and 92kD gelatinases; MMP2 
and 9) are expressed and active in the balloon-injured rat carotid 
artery. Although the systemic administration f drugs that affect 
the active site inhibits inrimal thickening, these drugs have a toxic 
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effect on the animals as the drugs must be administered by 
intraperitoneal injection. We can obtain the same inhibition of 
intimai thickening by introducing virally transduced smooth 
muscle cells overexpressing the natural inhibitor of MMPs, 
TIMP-1, without side effects. 
The current smooth muscle cell-based approach to gene 
transfer isnot likely to be of clinical utility because it is somewhat 
cumbersome and requires cell culture. Nevertheless, it provides 
proof of concept, which can then be exploited further when better 
direct gene transfer methods come on line. 
Conc lus ion  
We have been able to show that vascular smooth muscle cells 
can serve as useful vectors for transferring genes Of interest into 
blood vessels. Using smooth muscle cells transduced with replica- 
tion-defective r trovirus, we have been able to show that this 
approach is usefi,fl for systemic gene therapy, the development of
models of vascular disease, and local vascular pharmacology. 
Alexander W Clowes, MD 
University of Washington School of Medicine 
Seattle, Wash. 
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iNOS OVEREXPESSION TO MODIFY 
DISEASE STATES 
Normal human vascular physiology is dictated by an orchestrated 
array of counterregulatory mediators collaborating to maintain 
optimal tissue perfusion. One such mediator is endothelium- 
derived relaxing factor, first described in 1980, eventually identified 
as nitric oxide (NO) or a derivative thereof in 1987.1 This NO, 
originating from the endothelium from a resident constitutively 
expressed NO synthase nzyme (ecNOS or NOS-3), is a potent 
smooth muscle relaxant and is responsible for maintaining a state of 
resting vasodilation. NO has also been demonstrated to possess a
number of other vasoprotective properties. NO inhibits platelet 
adhesion and aggregation, and platelets themselves exhibit the 
capacity to synthesize an independent source of NO. In vitro data 
suggest that NO may inhibit vascular smooth muscle cell prolifera- 
tion through cell cycle arrest. Finally, NO may reduce leukocyte 
adherence and infiltration of the endothelial barrier. All of these 
functions may be essential defenses against vascular occlusive 
complications. 
The precise role of NO in the pathogenesis of vascular 
occlusive disorders uch as atheroscterosis and restenosis i still 
under intense investigation, but several studies hint at the relevance 
of NO depletion in the establishment and progression of these 
maladaptive states. An early event in the development of an 
atherosclerotic plaque is the accumulation of lipid-laden macro- 
phages in the intima with disturbance of the endothelium, z 
Endothefial NO synthesis may become impaired at these locations. 
In addition, oxidized lipoproteins have been demonstrated to
inactivate NO, thereby creating an environment that lacks NO. 
Diabetic patients are especially prone to an aggressive form of 
atherosclerosis. Their predilection may stem in part from progres- 
sive accumulation fglycosylated products that may also inactivate 
NO. Indeed, atherosclerotic arteries are less vasoresponsive to 
agonists uch as acetylcholine but are still able to vasodilate in 
response to authentic NO, suggesting reduced endogenous NO 
release. 
Vascular estenosis after therapeutic manipulation may also 
result from inadequate NO availability. Blood vessel injury is 
characterized by endothelial denudation with damage to the 
underlying smooth muscle cells. Exposed collagen and smooth 
muscle provide a prothrombogenic surface that invites leukocyte 
and platelet adhesion. A number of chemotactic and mitogenic 
factors are then released that facilitate cellular migration and 
proliferation, resulting in the creation of a neointima. It has been 
reported that the inducible NOS (iNOS or NOS-2) isoform is 
expressed transiently, beginning immediately and persisting for 1 to 
2 weeks, in arterial smooth muscle cells in response to balloon 
catheter-induced injury in rat carotid arteries? Unlike NOS-3, 
NOS-2 expression is detected in cells only after cytokine or 
mechanical perturbation, and the enzyme is several magnitudes 
more active in the absence ofagonist stimulation. NOS-2 induction 
as part of the vascular healing response may provide an alternate 
source of NO until endothelial integrity can be reestablished. 
Restenosis may derive from a defect in this response. 
Although the role of NO in the establishment of intimal 
hyperplasia s still unclear, the benefit of NO in preventing this 
response may be more evident. McNamara et al.4 reported a 39% 
reduction in intimai hyperplasia n injured rabbit carotid arteries 
with oral supplementation f the NOS substrata L-arginine. 
Similarly, Davies et ai.5 attenuated neointima formation by 47% and 
preserved vasoreactivity in vein grafts that were interposed in the 
carotid circulation with supplemental L-arginine alimentation. 
Finally, systemic administration of an NO donor 6 reduced the 
intimal thickness by 82% and accelerated reendothelialization n 
injured rat carotid arteries. These results, although indirect and in 
rodent models, strongly suggest he benefit of increased NO 
availability for the attenuation of the hyperplastic reaction to 
vascular injury. 
With these observations, the application of NO in the preven- 
tion ofrestenotic complications and even atherosclerosis may have 
therapeutic utility. To evaluate this hypothesis, a method of 
delivering a therapeutic dose of NO is necessary. One such option 
is systemic administration f NO donors. However, the potential 
for hypotensive side-effects i real. Also, the complexity of NO 
biology and all of its purported cytotoxic effects are incentives to 
localize NO exposure in a site-specific fashion. To achieve this, the 
best method may be gene transfer ofa NOS gene to sites of vascular 
injury at the time of therapeutic intervention, such as immediately 
after angioplasty. Indeed, vonder  Leyen et al. 7 examined the 
efficacy of liposome-mediated NOS-3 gene transfer at reducing 
intimal hyperplasia ina rat carotid artery injury model. The authors 
demonstrated reconstitution of NOS-3 activity in the injured 
